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Abstract: 
 
 Lynch syndrome, which is also known as hereditary nonpolyposis colorectal 
cancer (HNPCC), is estimated to account for approximately half of all heritable colon 
cancers and perhaps upward of 3% of all colon cancers in the western world. This 
amounts to approximately 4500 cases a year in the US alone.1 Lynch syndrome arises as 
a result of mutations in genes of the mismatch repair pathway, conferring an autosomal 
dominant cancer predisposition with an ~80% lifetime risk of HNPCC-associated 
cancers.1 Four mismatch repair (MMR) genes, MLH1, MSH2, PMS2 and MSH6, are 
typically implicated in the transmission of Lynch syndrome. 
 Large scale germline deletions within the mismatch repair gene MSH2 account for 
a significant proportion of all deleterious mutations in this gene, and cause HNPCC. A 
recently characterized deletion of exons 1 through 6 of MSH2 has been associated with a 
founder event within the United States which genealogical studies have previously dated 
to 1727.2 The sequencing of the breakpoints completed the characterization of the 
“American Founder Mutation” (AFM) and allowed for the separation of this deletion 
from that of other similar, but distinct, deletions via long-range PCR and sequencing.3,4 
Here, we report the development of a robust multiplex PCR which has assisted in the 
detection of 24 new families who carry the AFM and the subsequent characterization of 
20 patient haplotypes which flank the deletion. New genealogical data has identified a 
likely erroneous connection in the original pedigree analysis. As such, three further 
families have been linked to the original pedigree and we have now identified an 
alternative founding family dating to   
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1764, as well as five further “subfounder” groups, all of which date to the eighteenth 
century.  
 The use of molecular data, combined with extensive pedigree analysis, provides 
independent measures of the origins of the AFM, with significant implications for the 
mutation’s modern prevalence in America, which has been estimated to be nearly 19,000 
individuals.5 In this study, I have sought to gain further insight into the origin, 
occurrence, and spread of the AFM through improved genealogical and molecular genetic 
studies. 
 
**** 
 
Introduction:  
 All colorectal cancer (CRC) begins as a polyp which, if caught through screening 
methods such as colonoscopy, can be removed before becoming cancerous. As such, 
CRC is a truly preventable form of cancer, yet it is among the four most common forms 
of cancer in the United States, with approximately 150,000 individuals diagnosed each 
year.1 This makes CRC screening an important component of medical care from both a 
patient health viewpoint and an economic viewpoint.  
 Hereditary nonpolyposis colorectal cancer (HNPCC) is thought to account for 
upward up 3% of all CRC in the western world, and is the most common form of 
heritable CRC.1 It is caused by germline mutations in the mismatch repair (MMR) genes 
MLH1, MSH2, PMS2 and MSH6. As MMR genes are responsible for repairing errors 
that occur naturally during DNA replication, loss of function mutations in these genes 
lead to an accumulation of mutations in the rest of the cellular genome.6 When these 
mutations occur in other important genes which control transcription or apoptosis, the 
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cell may divide aberrantly forming an adenoma, and can eventually progress to form a 
HNPCC-associated cancer, including: colorectal, endometrial, renal pelvic, ovarian, 
stomach, and small bowel cancers, among other less common presentations.7  
 Mutations in the MMR gene MSH2 confer an autosomal dominant cancer 
predisposition with an ~80% lifetime risk of HNPCC-associated cancers,4 thus it is of the 
utmost importance to identify these at-risk patients so as to provide them with 
specifically focused medical examinations and treatments. As Alu repeats, which are 
highly repetitive sequences found in large numbers (100-500,000) in the human genome, 
occur frequently in MSH2,8 the gene is highly susceptible to large genomic deletions 
which result from non-homologous recombination. In America, the most common of 
these genomic rearrangements is a deletion of exons 1-6, which Baudhuin et al. (2005) 
found in 22 of 86 (25.6%) MSH2 deletion-positive samples.9 1-6 deletions have also been 
identified in many other countries including Poland, England, Italy, Holland, and 
Australia.  
 In the United States a recurring exon 1-6 deletion of MSH2 has been identified. 
This Alu-repeat mediated deletion was originally identified in 7 apparently unrelated 
American families with Lynch syndrome at the Creighton University School of 
Medicine.2  This discovery led to the screening of another 11 families, these at The Ohio 
State University, of which 2 possessed the same gene deletion.2 The existence of an 
identical large deletion such as this suggested that a founder mutation may exist in the 
United States, wherein an original progenitor introduced a novel mutation into the gene 
pool, and because of the small, rapidly growing American population, the aberrant-gene 
frequency became over-expressed.  
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Using genealogical data from the families possessing the AFM, 3 of the 9 families 
were purportedly linked through 9-10 generations to a common founder couple, who 
immigrated to America from Hesse, Germany in the early 1700’s.2   
The ultimate aim of my project has been to discover the age of the AFM in 
America, in order to accurately determine the modern disease prevalence which has been 
estimated at nearly 19,000 individuals5. Through the use of genealogical research, we 
have attempted to identify more accurately the true progenitor of the mutation by finding 
common ancestors who are shared by multiple AFM probands and to reconcile these 
ancestors with those proposed by Lynch et al., 2004. Additionally, we have utilized 
microsatellite markers to create patient haplotypes for twenty AFM probands. This 
molecular data can then be used to statistically determine the age of the mutation, based 
on the size of the conserved region and known rates of recombination. Finally, we have 
worked to develop a more robust PCR diagnostic tool to utilize in identifying additional 
probands who carry the AFM. An account on this work and my findings constitutes the 
remainder of this report.  
 
**** 
 
Methods:  
 
PCR Based Screening and Breakpoint Characterization: Previously published primer 
sets (Nakagawa et al., 2003; Wagner et al., 2003) for this procedure were not ideal due to 
their tendency to produce false negative results primarily because the product was 
relatively large and spanned across three complete and one partial Alu repeat. For this 
study, we positioned the forward primer (5-GCCTGGCGTCAAACGTT-3) in a region 
between two repeat elements that lacked homology to other human sequences.  
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 The reverse primer (5-TGAGTCATTTTGGGGATCAGTT-3) is very similar to 
the F3 primer utilized by Wagner et al (2003), however in combination with this new 
forward primer it produces a breakpoint-specific 562bp amplicon under standard PCR 
conditions. In order to ensure that poor DNA quality was not a reason for a negative 
result, this amplicon was multiplexed with an 811bp amplicon from the BRAF locus (For: 
5-AAGCATCTCACCTCATCCTAACACA-3, Rev: 5-GGATCACACCTGCCTTAAA 
TTGCAT-3), in a 15l PCR reaction.  Each 15l reaction, containing 7.5l of 
GoTaq® master mix (Promega), 25ng of genomic DNA and 5 pmoles of each of the 4 
primers, was cycled under the following conditions: 95oC for 2 min., 30 cycles of 95oC 
for 30 sec., 60oC for 30 sec. and 72oC for 45 sec., and a final extension at 72oC for 8 min. 
Samples with a breakpoint specific product were treated with ExoSAP-IT (USB 
Corporation) and sequenced with the forward primer to confirm the presence of an AFM 
specific breakpoint. (see Figure 1 below) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100bp    AFM     negative     no
ladder   sample    control    DNA
Breakpoint
Control
Figure 1: Agarose gel showing breakpoint specific PCR product 
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Genotype Analysis: A combination of 8 novel and 4 DeCode microsatellite markers 
were used to obtain a haplotype spanning ~12.48Mb across the MSH2 locus. 
Microsatelite markers were chosen in lieu of SNPs because the increased number of 
possible alleles allowed for more precise differentiation between genetic conservation 
due to chance and that due to shared descent. Markers (see figure 2) were typed in 20 
AFM positive probands (or their AFM positive kindred) and a set of 118 Coriell control 
DNAs.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 For each amplicon the reverse primer had an M13 tail which, in combination with 
a FAM labeled M13 oligo, could be sized using an ABI7000. Each 25l PCR reaction 
contained 12.5l of AmpliTaq Gold PCR master mix (Applied Biosystems), 25ng of 
genomic DNA, 10 pmoles of forward primer, 2 pmoles of tailed reverse primer and 10 
pmoles of the FAM-labeled M13 primer. Reactions were multiplexed when possible and 
cycled using the following profile: 96oC for 10 min., 50 cycles of 96oC for 30 sec., 60oC 
for 30 sec. and 72oC for 30 sec., and a final extension at 72oC for 10 min.  
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Figure 2: Graphical representation of the physical location of microsatellite markers 
flanking the MSH2 gene. Markers in red were utilized in the haplotype analysis. Novel 
and database markers are prefixed by Clen and D2S, respectively. 
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 The amplified product was sent for genotyping to determine the length of the 
labeled DNA amplicon. Polymorphisms in amplicon size, corresponding to differing 
numbers of microsatellite repeats, were scored as distinct alleles. The AFM-associated 
haplotype was inferred from a single haploid clone which was produced in a previous 
study by conversion to haploidy through fusion to a mouse recipient cell line.10  
 
Genealogical investigations: Historical records were utilized to construct pedigrees for 
all probands, focusing on those lines marked by heightened HNPCC-associated cancer 
frequencies. The pedigrees were analyzed to search for any relatives shared by multiple 
probands, and also for any relatives that descended from the purported founder couple. 
Data were obtained from state and county birth, death, and marriage records, and from 
online genealogy resources such as those provided by Ancestry.com and 
FamilySearch.org. Genealogical data were also obtained through patient interviews 
conducted at a genetic counseling center, or with patient permission, through a telephone 
interview.  
The lineage of the purported founders was also traced in order to link their 
descendants to the AFM families. Because this couple was instrumental in the creation of 
a German-Reformed Church in NC, the information concerning their descendants came 
from church records and local North Carolina genealogy enthusiasts, as well as the 
previously published research.2 In addition, a research team traveled to this church during 
an annual family reunion held there to gather ancestry information and perform genetic 
testing on 45 descendants of the purported founder.  
 
**** 
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Results: 
 
Identification of AFM carriers: The newly developed PCR was very successful in 
identifying AFM-positive individuals. The new primers resulted in no false negatives, 
unlike the previously published primers, and show great promise as a simple and 
inexpensive diagnostic tool for AFM screening. With the aid of this diagnostic, we have 
identified 24 new families with the AFM. Combined with the nine from the original 
study,2 we have identified 33 families in all.  
 Due to the sequence composition of the genomic region containing MSH2 (i.e. 
excessive numbers of Alu-like repeats), it is essential to confirm the exact breakpoint 
sequence of this deletion as it is very likely that other 1 through 6 deletions may occur as 
a result of recombination between alternate repeat elements or even at different locations 
within the same repeat elements.11 Each of these 33 probands have tested positive for the 
AFM using the new primers, save six of the seven original probands whose mutation 
status was confirmed using the previously published primers.  
 For each of the twenty probands whose DNA was used in the haplotype analysis, 
the samples were amplified using the new breakpoint specific primers and the products 
were sequenced to confirm the precise location of the break. All 20 of the samples were 
found to carry the same AFM specific mutation (see figure 3).   
 
 
 
 
 
 
 
  
 
GTCAATCTCCTGGGCTCAAGTGATCCGCCCACCTCGGCCTCCCAAATTGCTGGGATTACAGGCGTGAGCTACCGCGCCCTGC
GAGGCCAAGGTGGCCGGATTGCCTTGGCCTGCCTCAGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCTCAGGAGTTCGAG
5' of MSH2
MSH2 intron 6
Figure 3: Breakpoint sequencing chromatogram. Alignments above represent wild 
type sequences 5 and 3 to the breakpoint, with mismatches shown in a red font. The 
expected breakpoint region (10bp) is depicted in a bold font. 
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Genealogical Studies: To support the genetic evidence it was hoped it would be possible 
to link some or all of the proband families to the 18th-century German founders 
hypothesized by Lynch et al (2004). Careful analysis showed, however, that one of the 
three genealogical links made in this earlier study was based on inaccurate genealogical 
data, causing the likely misidentification of a founder. However, the other two families 
are, in fact, genealogically linked. Furthermore, we have now shown how three additional 
families from our ongoing study connect to those from the initial study (see figure 4). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
31416
25332
E
F G
I
II
IV
III
V
VI
VII
VIII
IX
Individual with an
HNPCC associated cancer
Adapted from 
Lynch et al., 2004
Clendenning, Walsh et 
al., 2007 Unpublished
D.O.B.
1702
D.O.B.
1764
D.O.B.
1827
33765
Figure 4: Pedigree showing the newly characterized genealogical link between three new 
probands and two of the originally linked families (Lynch et al., 2004). The female shown in pink 
depicts the common link between the two original families (F and G) and the three newly 
identified families (25332, 31416, and 33765). Evidence obtained in our studies has identified a 
likely erroneous link in the original pedigree (marked by a red X), which would suggest that the 
founder couple proposed by Lynch et al., 2004 (boxed in black) was misidentified. The new 
genealogical data presented here can trace the mutation back to one of two individuals (boxed in 
red). Currently, no data has been obtained for the female; however, we were able to trace all 4 of 
the male progenitor’s grandparents back to central Europe (Germany and Switzerland). 
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Of the 42 descendants of the previously proposed founders, each of whom was 
tested for the AFM during a family reunion held in North Carolina during the summer of 
2005, none were found to carry the mutation. This provides further evidence that the 
proposed German progenitors are part of a separate family tree which is only linked to 
the true AFM line by a single marriage event which occurred in 1832 (see figure 4) 
In addition to the above pedigree, 11 more families have been linked to each other 
through a total of six additional ancestral couples. I shall refer to these other pedigrees as 
“subfounder” lines, all of which have an oldest known common ancestor born in the 
United States during the 1700’s. While some of these couples actually predate those 
depicted in figure 4, I will continue to treat figure 4 as the primary pedigree because it 
connects the largest number of probands (5) to a single ancestral couple.  
The most interesting of the subfounder pedigrees connects 4 probands, 3 new and 
1 from the original study, to three separate ancestral couples dating to 1730, 1755 and 
1745 respectively (see figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DOB
1730
A
34222
25295
33530
No HNPCC cancer           
history in family
DOB
1753
DOB
1755
Individual with an
HNPCC associated cancer
Clendenning, Walsh et 
al., 2007 Unpublished
Striped individuals appear
in multiple pedigrees
DOB
1745
A
34222
3353025295
5A 5B 
Figures 5A & 5B: Four probands, three new and one from the original study, can be 
genealogically linked to three separate progenitor couples. For probands 25295, 33530 
and A, the four generations immediately preceding them are the same individuals 
(marked by stripes) in both pedigrees. However, in the case of patient 34222, the first 
pedigree connects through his mother and the second through his father.  
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Three plausible progenitor couples exist in the pedigree of these families as the 
result of a highly intermarried, extremely sedentary family history. As seen in figure 5, 
the first several generations preceding probands 25295, 335530, and A are the same 
individuals in both pedigrees. Proband 34222, however, is connected through his mother 
in the first pedigree (5A) and through his father in the second (5B). Although all three 
couples could be the one who passed along the AFM, there is evidence to point to the 
couple dating to 1745, depicted in the second pedigree. This is because patient 34222 had 
no HNPCC-related cancer history on his mother’s side of the family. While his father did 
not have an HNPCC-associated cancer either, his paternal aunt had colon cancer. This 
family history supports the hypothesis that it is the couple dating to 1745 (5B) who in fact 
passed on the AFM.  
Figures 6 through 8 depict three more pedigrees, which link an additional 7 
families (5 new, 2 from the previous study) to common ancestral couples dating to 1758, 
some time before 1800, and 1776 respectively (see figures 6,7, and 8).  
 
 
 
 
 
 
 
 
 
 Figure 6: Three probands, two newly identified (G.H. and 29679) 
and one from the original study (22880/ Family H) descend from a 
common ancestral couple dating to 1758.  
DOB 
1769 
DOB 
1758 
22880  
   (H) G.H. 
29679 
Individual with an 
HNPCC associated cancer 
Clendenning , Walsh  et  
al ., 2007 Unpublished 
I 
II 
IV 
III 
V 
VI 
VII 
VIII 
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 Despite the fairly long existence of the AFM in America, which dates back to at 
least 1755 based on pedigree analysis (see figure 5A), it would be presumptuous to 
assume that the mutation has dispersed equally across the U.S. As is the case with other 
I
II
III
30878
C
IV
V
VI
DOB
1817
DOB
1815
Individual with an
HNPCC associated cancer
Clendenning, Walsh et 
al., 2007 Unpublished
DOB
1778
DOB
1776I
II
III
D
IV
V
VI
Individual with an
HNPCC associated cancer
Clendenning, Walsh et 
al., 2007 Unpublished
L.A.VII
Figure 7: Two probands (one newly identified (30878) and one from the original 
study (C)) descend from a common ancestral couple predating the 18th century. 
Figure 7: Two probands (one newly identified (L.A.) and one from the original 
study (D)) descend from a common ancestral couple dating to 1776. 
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founder mutations12, 13, 14, the AFM appears to be over-expressed in certain regions. By 
looking at a proband’s family history, one can typically determine which side of the 
family carries the AFM. Plotting the ancestral residence of this side of the family tree on 
a map of the U.S. shows us that certain states contain a much higher proportion of AFM 
ancestral kindred than others (see figure 8). The distribution of the AFM that is seen 
likely has historical explanations.  
 One example of this is that three Texan families and a Californian family are all 
descended from a common female ancestor (see figure 4, marked in pink). This 
individual married a Mormon convert who moved from Tennessee to Alabama, before 
assuming a leadership role in the Church of Latter Day Saints in Utah. Following an 
excommunication from the church, he fled to California where he resided until his death. 
As shown from this example, a single individual who carried the AFM early in America’s 
history left a host of mutation-positive ancestors across the western United States.  
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Figure 8: Map of the United States showing, where possible, the location of the proband’s 
ancestral origins (used when the mutation-positive side of the family is clear or all four 
grandparents are from the same region). Red and green stars represent families that have been 
characterized in this study. Families that were also typed in the original study are shown in green. 
The great grandson of individual E is depicted as a green circled star. Three probands: 25332, 
31416, and 33765 (represented by red circled stars), were genealogically linked to families F and G 
from the original study (see figure 4). 
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 As 16 probands trace their ancestral origins to Kentucky, it is abundantly clear 
that the AFM is overexpressed in that state, especially the Southeastern region. For a 
more detailed view of the state, see figure 9. Bell County, KY in particular has an 
abundance of historical individuals who carried the AFM, as five probands trace their 
ancestry to that one county. This happens to be the county where the Cumberland Gap is 
located, which was the main passage for pioneers heading west from Virginia and the 
Carolinas. This supports our hypothesis that the AFM is a founder mutation which came 
to America from Europe and later spread westward with early settlers and is not, instead, 
a much older aboriginal mutation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genotype Characterization: To link the probands genetically, and rule out the 
possibility that affected families were acquiring the mutation de novo, we typed a set of 
Figure 9: Expanded map of Kentucky showing, by county, the location of 16 proband’s 
ancestral origins (used when the mutation-positive side of the family is clear or all four 
grandparents are from the same region). Red and green stars represent families that have been 
characterized in this study. Families that were also typed in the original study are shown in 
green. Highlighted counties include Barren, Bell, Campbell, Breathitt, Garrard, Johnson, 
Knox, Letcher, Madison, Perry, Pulaski, and Trigg.  
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polymorphic microsatellite markers which flanked the mutation site. A panel of 12 
microsatellites was chosen which flanked the mutation site and had an average interval of 
956Kb (range: 120Kb-2Mb). We optimized microsatellite selection based on three 
criteria: 1) the repeat had to be highly polymorphic to reduce the likelihood of similarity 
by chance 2) the microsatellite and its flanking sequence had to be unique within the 
genome 3) the repeat could not be located close to, or within, a more complex repeat such 
as an Alu which can often introduce additional size variation due to poly A tracts and can 
cause problems with primer binding due to the excessive prevalence of Alus.  
 The use of a haploid cell line from one of the patients, 20600, enabled us to 
generate an inferred haplotype for all 20 patients (see figure 10) and demonstrated that all 
patients shared a common disease haplotype. Analysis demonstrated a conserved 
haplotype of some 2.67-7.10 Mb in most cases, but a much smaller haplotype (0.59-2.67 
Mb) in a single case, which would formally indicate that the mutation is considerably 
older than initially believed.  
 Because we have hypothesized that patients possessing the AFM inherited it from 
a common founder, we expect the haplotype data to show that the 20 individuals are more 
closely related than a random outbred sample of Americans. Additionally, we anticipated 
that our within-group variance would be lower between individuals who have been 
genealogically linked to one-another, as they would ostensibly be more related to each 
other than to any of the other AFM patients. Looking at the haplotypes of the subgroups 
that have been linked, we can see that they do, in fact, most resemble the haplotypes of 
the other patients to which they have been genealogically linked (see figure 11). 
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Patient ID AFM
†
D2S391 Clen29 D2S2156Clen32 Clen33 Clen30 Clen25D2S2306 D2S119 Clen27
20600 4 7 1 2 4 1 2 6 2 4
20600 4 1 7 7 1 6 2 2 4 7 1 5 Yes 2 2 6 10 2 6 4 3
25480 4 1 6 7 1 1 2 5 4 3 1 1 Yes 2 2 6 4 2 7 4 4
26811 4 1 6 4 1 6 2 2 4 6 1 2 Yes 2 2 6 1 2 5 4 5
22880 1 2 6 3 1 1 2 5 4 3 1 3 Yes 2 1 6 8 2 5 4 6
25208 1 1 6 4 1 1 2 2 4 3 1 3 Yes 2 4 6 9 2 5 4 2
25443 1 1 6 4 1 1 2 1 4 7 1 2 Yes 2 3 6 10 2 5 4 5
25954 1 3 6 3 1 4 2 3 4 1 1 3 Yes 2 3 6 9 2 5 4 4
29679 1 1 4 2 1 3 2 1 4 4 1 1 Yes 2 3 6 7 2 5 4 4
26737 1 1 6 1 1 1 2 4 4 4 1 1 Yes 2 1 6 11 2 5 4 5
30462 4 3 4 4 1 6 2 2 4 7 1 1 Yes 2 3 6 10 2 5 4 5
25332 1 2 6 5 1 7 2 4 4 4 1 5 Yes 2 1 6 3 2 6 2 5
31416 1 1 4 5 4 6 2 3 4 4 1 1 Yes 2 1 6 8 2 4 2 5
24342 4 4 1 5 2 6 2 4 4 5 1 3 Yes 2 3 6 8 3 3 2 5
25295 1 1 6 1 1 1 2 2 4 4 1 3 Yes 2 1 5 9 5 6 6 5
29649 1 1 1 4 1 1 4 5 4 4 1 1 Yes 2 2 7 9 5 5 1 6
n/a n/a 37% 30% 47% 58% 26% 3% 3% 17%
Population 
frequency of 
disease allele
33859 1 1 4 5 1 2 2 2 4 4 1 1 Yes 2 1 6 2 2 5 4 4
33765 1 3 5 5 1 6 2 2 4 4 1 3 Yes 2 1 6 3 1 6 2 7
30878 1 4 3 3 1 3 2 2 4 7 1 1 Yes 2 2 2 11 5 6 2 6
34222 1 1 * * 1 6 2 2 4 3 1 1 Yes 2 1 5 9 5 5 5 6
33530 1 2 1 4 1 1 2 5 4 2 1 4 Yes 2 3 7 10 1 5 3 6
Clen43
3
3 6
3 5
3 4
3 5
3 3
3 5
3 5
3 6
5 6
3 4
3 5
3 5
3 5
5 5
3 5
12%
3 5
1 5
4 6
3 5
5 6
Clen44
4
4 7
1 2
4 4
4 7
4 2
2 3
2 3
4 8
2 7
2 6
2 5
5 5
5 5
4 6
4 2
n/a
2 2
2 6
4 3
4 6
4 5
33765 1 3 5 5 1 6 2 2 4 4 1 3 Yes 2 1 6 3 1 6 2 7 1 5 2 6
25332 1 2 6 5 1 7 2 4 4 4 1 5 Yes 2 1 6 3 2 6 2 5 3 5 2 5
31416 1 1 4 5 4 6 2 3 4 4 1 1 Yes 2 1 6 8 2 4 2 5 3 5 5 5
34222 1 1 * * 1 6 2 2 4 3 1 1 Yes 2 1 5 9 5 5 5 6 3 5 4 6
25295 1 1 6 1 1 1 2 2 4 4 1 3 Yes 2 1 5 9 5 6 6 5 5 5 4 6
33530 1 2 1 4 1 1 2 5 4 2 1 4 Yes 2 3 7 10 1 5 3 6 5 6 4 5
22880 1 2 6 3 1 1 2 5 4 3 1 3 Yes 2 1 6 8 2 5 4 6 3 5 4 7
29679 1 1 4 2 1 3 2 1 4 4 1 1 Yes 2 3 6 7 2 5 4 4 3 6 4 8
n/a n/a 37% 30% 47% 58% 26% 3% 3% 17%frequency of 
disease allele
12% n/a
Population 
Patient ID AFMD2S391 Clen29 D2S2156Clen32 Clen33 Clen30 Clen25D2S2306 D2S119 Clen27 Clen43 Clen44
Figure 10: Genotype data for 20 AFM individuals. Conserved disease haplotype is highlighted in yellow (data 
inferred from a single haploid clone†). Allele frequencies are determined from a set of 118 control DNAs. 
 
Figure 11: Genotype data for 8 AFM individuals pulled from figure 10. These haplotypes are divided into three 
subgroups that have been demonstrated to share common ancestors. Patients 33765, 25332 and 31416 share a 
common ancestral couple 6 generations removed (see figure 4). Patients 34222, 25295 and 33530 share 3 
common ancestral couples who are 5-7, 6-8 and 7-9 generations removed (see figures 5A and 5B). Patients 
22880 and 29679 share a common ancestral couple 6-7 generations removed (see figure 6). 
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**** 
 
Discussion:  
 
 In this study we identified 24 additional families that carry the AFM. Coupled 
with the nine families from the previous study this makes a total of 33 families spread 
throughout the United States. As mutations in MSH2 account for a significant proportion 
(1-2%) of all cases of colorectal cancer1, it is important to assess the risk that can be 
attributed to specific frequent mutations. Additionally, genomic rearrangements 
constitute a large proportion (10-20%)3 of all mutations in MSH2, and have been reported 
to constitute even larger proportions of some samples (45.4-50.0%) 4,9. The AFM appears 
to be the most common of these rearrangement mutations (33-75%).9,4   
 By using both genealogical analysis and haplotype data, we hoped to 
independently determine both an historical and a molecular estimate for the age of the 
mutation. At this time we can conclude, based on the genealogy, that the AFM has 
existed in the United States for at least 250 years (see figure 5A). Five pedigrees have 
identified a total of seven couples, each of which is ancestral to multiple AFM patients. 
These ancestors lived sometime before 1800 and are likely connected by pedigree to a 
still earlier couple who is ancestral to all our families.  
 Genotype analysis of 20 individuals demonstrated a conserved haplotype of some 
2.67-7.10Mb in most cases, but a much smaller haplotype (0.59-2.67Mb) in a single case, 
which would indicate that the mutation is, perhaps, considerably older than initially 
believed. Given that the AFM has not been seen outside the United States, we are left 
with two possible explanations for our findings.  
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 1.) The mutation is older than previously thought and exists outside the United 
States in regions in which it has not yet been detected. In this case the mutation may have 
been introduced into the U.S. by two or more individuals. 
 2.) The short haplotype (29649) is a result of frequent recombination events 
occurring within and around MSH2 due to the many Alu repeat elements, or due to 
microsatellite mutations, which occur in dinucleotide repeat elements at a frequency in 
the range of   10-3-10-4 times per locus per meiosis.15 Given that the haplotype data 
contains a total of 12 markers genotyped on 20 patients who descend from a shared 
ancestor at least 10 generations removed from our probands, this provides a minimum 
200 meiotic divisions and thus 2400 opportunities for a single germline MSR mutation to 
have occurred (20x10x12). Thus, it is likely that some of our patient markers differ from 
the disease haplotype due to MSR mutations as well as Alu-mediated recombination 
events. These phenomena may explain the short haplotype, in which case the AFM could 
have been introduced by a single founder who was de novo for the mutation or whose 
blood relatives did not pass the AFM on to descendants in Europe where we have 
screened for the AFM.  
 The age of the mutation based upon the molecular data remains to be determined, 
but considering what is now known, prevalence estimates based on a single European 
founding event predating the 1750’s should provide a conservative but reasonable 
estimate of the true prevalence of the AFM.  
 The spread of the AFM can be qualitatively viewed in several ways. Based on 
ancestral locations, we see it appearing in 7 states. Today it can be found in 17 states, 
which contain more than half of the American population, as well as the U.K. (16 state
 - 21 - 
identified by Lynch et al (2006), plus newly identified patients in Iowa and England). 
Overall, the spread of the AFM seems substantial and only stands to increase over time.  
 With a founding event predating 1750 in a nation which underwent rapid 
population growth and westward expansion due to large family sizes and increased 
mobility, the AFM has become a widespread mutation. It is perhaps the second most 
common mutation in MSH2, after the intronic germline A-->T point mutation at nt942+3, 
which frequently occurs de novo and accounts for 11% of all known pathogenic MSH2 
mutations.16
 Because it is extremely important to screen for CRC in individuals with MMR 
mutations, it is vital that these mutations be identified and that the frequency of 
colonoscopy screenings for such individuals be increased to occur at least biannually 
starting at age 20, as in accordance with the recommendations of the International 
Collaborative Group on HNPCC.7 It is also vital to determine the nature of these MMR 
mutations so that family members can receive targeted genetic testing followed by 
increased screenings for those determined to have a germline MMR mutation.  
 In the case of the AFM, the newly developed diagnostic PCR provides an 
inexpensive and highly accurate method of detecting the mutation. As the AFM appears 
to be very common throughout the United States, especially in the Midwest and Texas, 
we propose that the new PCR test should be used as a method of primary mutation testing 
for individuals already found to have a loss of MSH2 protein expression via 
immunohistocompatibility. Additionally, the test has applicability for patients with an 
undiagnosed MSH2 mutation which was not elucidated by genomic sequencing, or for 
individuals determined to have a genomic deletion of MSH2 as determined by Multiplex 
 - 22 - 
Ligation-dependent Probe Amplification (MLPA17). This could prove especially effective 
in the regions determined to be geographic hotspots for the mutation and has real 
implications for cancer prevention and control.  
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